During the past decade, Kidney Cancer Research Bureau conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Kidney Cancer Research Bureau" are "Metastatic Renal Cell Carcinoma" (1 trials), "Non-small Cell Lung Cancer Metastatic" (1 trials), "Pleural Effusion, Malignant" (1 trials) and "Renal Cell Cancer Metastatic" (1 trials). Many other conditions were trialed in "Kidney Cancer Research Bureau" in a lesser frequency.

Most popular intervention types in "Kidney Cancer Research Bureau" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Nivolumab" (1 trials) and "Testosterone undecanoate and sunitinib or pazopanib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Kidney Cancer Research Bureau" are 1 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Kidney Cancer Research Bureau". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Kidney Cancer Research Bureau, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Kidney Cancer Research Bureau, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".